Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Weight Maintenance (SCALE Maintenance)
NCT00781937Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2008
- Primary completion
- Sep 2010
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of liraglutide in obesity and Overweight (2 arms), sponsored by Novo Nordisk. Primary endpoints: Mean Percentage Change in Fasting Body Weight From Baseline at 56 weeks, Percentage of Subjects Who Maintained Their run-in Fasting Weight Loss From Week 0 at 56 weeks and 1 more. Started Oct 2008; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT00781937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781937.